Page 9 - Read Online

Angelini. J Transl Genet Genom 2024;8:244-8 https://dx.doi.org/10.20517/jtgg.2024.29 Page 248

Copyright
© The Author(s) 2024.

REFERENCES
1. Bonifati DM, Witchel SF, Ermani M, Hoffman EP, Angelini C, Pegoraro E. The glucocorticoid receptor N363S polymorphism and
steroid response in Duchenne dystrophy. J Neurol Neurosurg Psychiatry 2006;77:1177-9. DOI PubMed
2. Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr
2001;138:45-50. DOI PubMed
3. Guglieri M, Bushby K, McDermott MP, et al. Effect of different corticosteroid dosing regimens on clinical outcomes in boys with
duchenne muscular dystrophy: a randomized clinical trial. JAMA 2022;327:1456-68. DOI
4. Smith EC, Conklin LS, Hoffman EP, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim
analysis of a non-randomized open-label extension study. PLoS Med 2020;17:e1003222. DOI PubMed PMC
5. Angelini C, Pinzan E. Advances in imaging of brain abnormalities in neuromuscular disease. Ther Adv Neurol Disord
2019;12:1756286419845567. DOI PubMed PMC
6. Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy.
Cochrane Database Syst Rev 2016;2016:CD003725. DOI PubMed PMC
7. McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in
patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 2018;391:451-61. DOI
8. Okubo M, Noguchi S, Hayashi S, et al. Exon skipping induced by nonsense/frameshift mutations in DMD gene results in Becker
muscular dystrophy. Hum Genet 2020;139:247-55. DOI PubMed PMC
9. Sheikh O, Yokota T. Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update. Arch Toxicol
2022;96:1-9. DOI PubMed
10. Straub V, Guglieri M. An update on Becker muscular dystrophy. Curr Opin Neurol 2023;36:450-4. DOI PubMed PMC